Viatical Settlements and HIV/AIDS: History and Modern Options

The AIDS Crisis and the Birth of an Industry

Before the late 1980s, a life insurance policy held by a dying person was economically inert: it would pay at death, but it could not help with the cost of dying. The AIDS epidemic changed that with terrible urgency.

Tens of thousands of predominantly young men — many with employer or individually purchased life insurance and few other assets — faced a disease that was then almost uniformly fatal, with staggering costs: hospitalizations, experimental drugs, home care, and lost income, often compounded by estrangement from family and discrimination that cost people jobs and housing. Out of that need, the first viatical settlement companies emerged around 1988–1989, offering to purchase policies from the dying for immediate cash.

The legal foundation already existed. The U.S. Supreme Court had held in Grigsby v. Russell (1911) that a life insurance policy is transferable property that its owner may sell. What the AIDS crisis supplied was the first large-scale market of willing sellers — and the name: viaticum, the provisions given a traveler before a journey.

The early market was genuinely double-edged. For many sellers it was dignity-preserving liquidity when nothing else existed — money for rent, care, and final wishes on the seller’s own terms. But it was also unregulated: pricing was opaque, some buyers paid pennies on the dollar to desperate people, and fraud occurred on both sides. Both realities — the legitimate need and the abuses — drove everything that came next.

How That Era Built Today’s Consumer Protections

Nearly every protection a policy seller enjoys today traces to lessons learned in the AIDS-era viatical market.

State regulators moved first. The National Association of Insurance Commissioners adopted its original Viatical Settlements Model Act in 1993 — before the broader life settlement market existed — establishing provider licensing, mandatory disclosures, and payment standards. That framework evolved into today’s Life Settlements Model Act, which most states have adapted. Its viatical-era DNA is visible in provisions such as:

• Minimum payout percentages tied to life expectancy bands for viatical sales, a direct response to lowball offers made to dying sellers;
• Escrow requirements, ensuring sellers are actually paid before ownership transfers;
• Rescission windows of 15–30 days, including provisions unwinding the sale if the insured dies during the window;
• Privacy limits on how often buyers may contact insureds for status checks — born specifically of complaints from AIDS patients fielding intrusive calls;
• Broker and provider licensing with state insurance department oversight — in New Jersey, under the Viatical Settlements Act in N.J.S.A. Title 17B, enforced by the NJ DOBI.

Congress contributed the tax piece: HIPAA in 1996 added IRC Section 101(g), making viatical proceeds for terminally ill insureds generally income-tax-free — an acknowledgment that these were, in substance, death benefits arriving early. The full mechanics are in our tax exclusion guide. For sellers today, the practical inheritance is simple: verify licensing, expect written disclosures, and know that the law was written with someone in your position in mind.

The Protease Inhibitor Shock: When Sellers Outlived the Market

In 1996, highly active antiretroviral therapy — built around protease inhibitors — transformed HIV almost overnight from a fatal disease into a survivable one. It was one of medicine’s great triumphs, and it is also the settlement industry’s most instructive case study in life expectancy risk.

Investors who had purchased policies from AIDS patients priced on expectancies of months suddenly held policies on people who would live decades. Funds collapsed; returns evaporated; litigation followed. Several lessons from that shock still shape the market:

• Underwriting became professional. The industry moved from informal physician estimates to specialized life expectancy firms producing methodology-driven reports — the independent LE reports that anchor every transaction today, typically two per file.
• Medical volatility is priced. Underwriters now explicitly consider the possibility of therapeutic breakthroughs, particularly for diagnoses where treatment pipelines are active.
• The market diversified. The industry shifted its center of gravity from viatical sales to senior life settlements, where mortality is driven by age and multiple impairments rather than a single disease with breakthrough risk — the market described in what is a life settlement.
• For sellers, the lesson runs the other way. A sale is irreversible after the rescission window; the protease inhibitor generation demonstrated that prognosis can change. Anyone selling while a promising therapy is emerging for their condition should weigh timing consciously.

For people living with HIV, of course, the shock was the point: survival. And that survival is precisely what changed how HIV interacts with the settlement market today.

Era	Medical Reality of HIV	Settlement Market Status	Key Protections in Place
1988–1995	AIDS almost uniformly fatal; life expectancy often months	Unregulated viatical market emerges; opaque pricing, documented abuses alongside genuine lifelines	Almost none initially; NAIC Viatical Model Act arrives 1993
1996–early 2000s	Protease inhibitors transform survival	Viatical investors suffer losses as sellers outlive estimates; industry professionalizes underwriting	IRC 101(g) tax exclusion (1996); state licensing spreads
Mid-2000s–2010s	HIV becomes managed chronic condition	Market pivots to senior life settlements; viatical volume shrinks	NAIC Life Settlements Model Act framework; escrow, rescission, anti-STOLI rules
Today	Near-normal lifespan with treatment; carriers underwrite controlled HIV	Controlled HIV = ordinary life settlement analysis; advanced HIV-related illness can still qualify as viatical	Full state licensing regimes; mandatory disclosures incl. ADB alternative; 101(g) exclusion for terminal cases

HIV Today: Usually a Life Settlement Question, Not a Viatical One

With sustained antiretroviral therapy, a person diagnosed with HIV today can generally expect a near-normal lifespan. That medical reality has a direct settlement consequence: well-controlled HIV does not meet the terminal-illness definition — a physician-certified life expectancy of 24 months or less — and therefore does not qualify for viatical treatment or the automatic 101(g) tax exclusion.

Instead, a policyholder living with well-managed HIV is evaluated like anyone else with a chronic health condition:

• As a health impairment in ordinary life settlement underwriting. HIV and its comorbidities (cardiovascular disease, kidney disease, certain cancers appear at somewhat elevated rates even with treatment) may shorten underwritten life expectancy modestly relative to standard tables, which improves pricing at the margin — the dynamic explained in how health affects life settlement value.
• Subject to the usual qualification profile: generally age 65+ (younger with significant impairments), face value around $100,000+, policy in force two-plus years, permanent or convertible coverage — see who qualifies for a life settlement.

There is a demographic reality behind this: long-term survivors of the epidemic are now in their 60s and 70s — squarely in life settlement territory by age alone. Many hold older policies purchased decades ago whose original purpose has passed. For that generation, the relevant analysis is ordinary settlement pricing per GAO-documented norms of 10–35% of face value, against alternatives like surrender or reduced paid-up coverage — compared honestly in settlement versus surrender.

When HIV-Related Illness Still Supports a Viatical Settlement

The viatical door has not closed for everyone affected by HIV. Situations that can still meet the terminal or chronic illness definitions include:

• Advanced AIDS with treatment failure. A minority of patients face multidrug resistance or cannot tolerate therapy; with opportunistic infections and declining function, physicians may certify a life expectancy within 24 months.
• Late diagnosis. People diagnosed only after progression to advanced AIDS — still a real occurrence — may qualify during the period before therapy takes hold, though successful treatment would change the picture.
• HIV-associated malignancies and organ failure. Certain lymphomas, liver disease from hepatitis co-infection, and end-stage kidney disease can independently support terminal certification — the same analysis as any terminal cancer viatical.
• Chronic-illness qualification. HIV-associated neurocognitive decline or profound functional impairment causing two-plus ADL deficits can satisfy the chronic illness definition, with the narrower tax exclusion that entails.

For anyone in these circumstances, the sequence matters: first, ask the carrier about the accelerated death benefit rider — a faster path that preserves part of the death benefit for beneficiaries; second, obtain the physician certification in writing, since it drives both qualification and the IRS 101(g) exclusion; third, seek competing offers only from licensed providers. Full criteria are in who qualifies for a viatical settlement.

Insurance Access, Old Policies, and What They Are Worth Now

The relationship between HIV and life insurance underwriting has its own history, and it affects what policies exist to be sold.

For roughly three decades after the epidemic began, an HIV diagnosis was an absolute bar to buying individually underwritten life insurance. People diagnosed before purchasing coverage typically could obtain only group coverage through employment, guaranteed-issue products with small face amounts, or nothing. That changed in the mid-2010s, when major carriers began underwriting applicants with well-controlled HIV — reflecting the same survival data that moved HIV out of viatical territory.

The result is three distinct policy populations today:

• Pre-diagnosis policies purchased before the insured acquired HIV — often decades old, sometimes with valuable guarantees. These are fully marketable, and for older insureds they can be strong settlement candidates.
• Group and employer certificates. Often sellable only if converted to individual coverage or assigned; conversion deadlines are unforgiving, so anyone leaving employment should check them immediately.
• Newer underwritten policies issued to people with controlled HIV — generally too recent, and their insureds too healthy, for settlement to make sense yet; the two-year in-force minimum applies regardless.

Whatever the policy’s origin, if premiums have become the problem, review the options short of lapse before letting coverage go — a lapse extinguishes both the death benefit and any settlement value. And policy sellers of every kind should understand what medical information changes hands, covered in our medical records guide.

Lessons the Viatical Story Teaches Every Seller

The HIV/AIDS chapter is not just history — it is a compact education in how to sell a policy wisely under any diagnosis.

• Desperation prices badly. The worst outcomes of the early market involved sellers who took the first offer. Competitive bidding among multiple licensed providers, or engaging a licensed broker with a fiduciary-style duty to the seller, is how offers reach fair value.
• Verify licensing every time. The entire regulatory apparatus — licensing, disclosures, escrow, rescission — only protects sellers who transact inside it. A five-minute check with the state insurance department is non-negotiable.
• Prognosis is probabilistic. The protease inhibitor shock proved that life expectancy estimates can be spectacularly wrong in both directions. Sell with that humility: the transaction is permanent after rescission, whatever medicine does next.
• Taxes reward documentation. The 101(g) exclusion, created for exactly these sellers, turns on a written physician certification and a licensed buyer. Paper both.
• Benefits interact. Lump sums can disrupt means-tested programs — Medicaid above all, a lifeline for many people with HIV through the epidemic and since. Plan the spend-down before funds arrive, as covered in our Medicaid guide.
• Alternatives first. The modern disclosure regime exists to make sure sellers know about accelerated death benefits, loans, and reduced coverage options before signing away the whole benefit.

The market that began at hospital bedsides in 1989 is now a regulated, institutional one — and the sellers it was built to protect remain at the center of how it is supposed to work. The full modern playbook is our complete viatical settlement guide.

---

Frequently Asked Questions

Can a person living with HIV sell their life insurance policy today?

Yes — the question is which market applies. Someone with well-controlled HIV on antiretroviral therapy is evaluated as an ordinary life settlement candidate: generally 65 or older (younger with significant health impairments), with a permanent or convertible policy of roughly $100,000-plus face value, in force at least two years. HIV and its comorbidities may modestly improve pricing as underwritten impairments. Only advanced HIV-related illness with a life expectancy under 24 months qualifies for viatical treatment.

Why did viatical settlements start with the AIDS crisis?

Because the need was unprecedented. In the late 1980s, tens of thousands of mostly young people faced a then-fatal disease with crushing costs and few assets beyond life insurance. The Supreme Court’s Grigsby v. Russell decision had long established that policies are sellable property, and around 1988–1989 the first companies began buying policies from the dying for immediate cash. The industry’s name comes from viaticum — provisions for a journey — reflecting those origins.

Are viatical settlement proceeds tax-free for someone with advanced AIDS?

Generally yes, if the terminal-illness standard is met. IRC Section 101(g) — enacted in 1996 with exactly these sellers in mind — treats proceeds paid by a licensed viatical settlement provider to an insured certified by a physician with a life expectancy of 24 months or less as death benefits, which are excluded from income. Chronic-illness qualification carries a narrower exclusion tied to long-term care costs. Keep the certification in writing and verify the buyer’s license.

What happened to investors who bought policies from AIDS patients in the 1990s?

Many suffered severe losses when protease inhibitor therapy arrived in 1996 and sellers — mercifully — lived decades beyond their estimated life expectancies. Funds built on months-long mortality assumptions collapsed, and litigation followed. The episode professionalized the industry: specialized life expectancy underwriting firms, typically two independent reports per transaction, and explicit modeling of medical-breakthrough risk all trace to that shock. It remains the defining cautionary tale about life expectancy uncertainty on both sides of these transactions.

Does well-controlled HIV increase the value of a life settlement at all?

Modestly, sometimes. Settlement pricing is driven by underwritten life expectancy, and even well-treated HIV can carry somewhat elevated rates of cardiovascular, kidney, and certain other conditions that shorten estimates relative to standard tables — which improves offers at the margin. But the effect is far smaller than for the serious impairments that drive strong pricing. For most people with controlled HIV, age, other health conditions, policy economics, and premium structure will matter more than the HIV itself.

Should someone with HIV-related illness check their accelerated death benefit before selling?

Absolutely — it is the correct first step under any serious diagnosis. Many policies contain riders paying 25–75% of the death benefit directly from the carrier upon terminal illness certification, faster than any sale and while preserving the remainder for beneficiaries. State disclosure laws require settlement sellers be informed of this alternative precisely because it is so often overlooked. Get the carrier’s quote in writing, then compare it against actual net offers from licensed providers.

Can I sell an old group life insurance policy from my employer if I have HIV?

Possibly, but conversion is usually the gateway. Group certificates generally must be converted to individual policies or assigned before they can be sold, and conversion privileges expire on strict deadlines — often tied to leaving employment or reaching a stated age. Long-term survivors who obtained group coverage during the years individual underwriting excluded people with HIV should check conversion rights before retirement or job changes, because a lapsed group certificate has no settlement value at all.

How did the AIDS era shape the consumer protections in today’s settlement laws?

Almost every modern protection answers a specific abuse from that period. Minimum viatical payout percentages respond to lowball offers made to dying sellers; escrow requirements ensure payment actually arrives; 15–30 day rescission windows allow reconsideration; contact-frequency limits stop intrusive status checks that AIDS patients endured; and licensing with state oversight professionalized the buyer side. The NAIC’s 1993 Viatical Settlements Model Act, later folded into the broader Life Settlements Model Act, carried these rules into most states’ laws.

Related Reading

• Viatical Settlement Complete Guide
• Who Qualifies Viatical Settlement
• What Is A Life Settlement
• How Health Affects Life Settlement Value

---

Pine Lake Life Solutions does not purchase life insurance policies and does not provide legal, tax, or investment advice. Information provided is for educational purposes only. Eligibility for any option, including life settlements, is not guaranteed and depends on individual circumstances, policy terms, underwriting, and market conditions. Consult independent legal, tax, or financial professionals before making decisions regarding a life insurance policy.